Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Sort descending Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Verzenio abemaciclib Adjuvant treatment of HR-positive, HER2-negative early breast cancer Reimburse with clinical criteria and/or conditions Complete
Zytiga (Resubmission) Abiraterone Prostate Cancer Resubmission Withdrawn
Zytiga Abiraterone Withdrawn
Zytiga Abiraterone acetate Metastatic Castration Resistant Prostate Cancer Reimburse with clinical criteria and/or conditions Complete
n/a abiraterone acetate and prednisolone High-risk non-metastatic prostate cancer Reimburse with clinical criteria and/or conditions Complete
N/A abiraterone, prednisone, docetaxel Metastatic castration sensitive prostate cancer (mCSPC) Reimburse Complete
Dysport Therapeutic abobotulinumtoxinA lower limb spasticity Reimburse with clinical criteria and/or conditions Complete
Dysport Therapeutic abobotulinumtoxinA Upper limb spasticity Reimburse with clinical criteria and/or conditions Complete
Dysport Therapeutic abobotulinumtoxinA Cervical dystonia Reimburse with clinical criteria and/or conditions Complete
Cibinqo abrocitinib Atopic dermatitis, moderate to severe Reimburse with clinical criteria and/or conditions Complete